Last reviewed · How we verify
Peginterferon alfa-2b (PEG2b)
Peginterferon alfa-2b (PEG2b) is a pegylated form of interferon alfa-2b, which works by stimulating the body's immune system to fight viral infections.
Peginterferon alfa-2b (PEG2b) is a pegylated form of interferon alfa-2b, which works by stimulating the body's immune system to fight viral infections. Used for Chronic hepatitis C, Chronic hepatitis B.
At a glance
| Generic name | Peginterferon alfa-2b (PEG2b) |
|---|---|
| Also known as | SCH 054031 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Interferon |
| Target | Interferon-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Virology |
| Phase | Phase 3 |
Mechanism of action
PEG2b achieves this by binding to the interferon-alpha receptor, triggering a cascade of signaling events that ultimately lead to the production of antiviral proteins and the activation of immune cells. This results in the inhibition of viral replication and the enhancement of the body's natural defenses against viral infections.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
- Myalgia
- Nausea
Key clinical trials
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) (PHASE3)
- Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) (PHASE3)
- Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548) (PHASE3)
- Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1) (PHASE3)
- Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599) (PHASE3)
- Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peginterferon alfa-2b (PEG2b) CI brief — competitive landscape report
- Peginterferon alfa-2b (PEG2b) updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI